EGFR and in situ carcinoma: In addition, some studies have also shown that pathologic characteristics in tumor tissues, such as the epidermal growth factor receptor (EGFR) mutation, human epidermal growth factor receptor type 3 (HER3), were differentially expressed during the progression of GGN from carcinoma in situ to invasive carcinoma [10,11,12].